In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur?

Kleinschmidt, Sharon L., Munckhof, Wendy J. and Nimmo, Graeme R. (2006) In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur?. International Journal of Antimicrobial Agents, 27 2: 168-170. doi:10.1016/j.ijantimicag.2005.10.009


Author Kleinschmidt, Sharon L.
Munckhof, Wendy J.
Nimmo, Graeme R.
Title In vitro exposure of community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains to vancomycin: does vancomycin resistance occur?
Journal name International Journal of Antimicrobial Agents   Check publisher's open access policy
ISSN 0924-8579
1872-7913
Publication date 2006-01-01
Sub-type Article (original research)
DOI 10.1016/j.ijantimicag.2005.10.009
Volume 27
Issue 2
Start page 168
End page 170
Total pages 3
Editor A. M. Geddes
Place of publication Amsterdam, Netherlands
Publisher Elsevier BV
Language eng
Subject C1
321010 Infectious Diseases
730101 Infectious diseases
Abstract Vancomycin is the preferred parenteral antibiotic for the treatment of all methicillin-resistant Staphylococcus aureus (MRSA) infections, including the newly emerging community-associated MRSA (CA-MRSA) infections. Vancomycin-intermediate nosocomial MRSA strains have developed in vitro and in vivo after exposure to vancomycin. The aim of this study was to determine whether daily serial passage of CA-MRSA strains onto vancomycin-supplemented agar selects for the development of vancomycin resistance. Twelve clinical isolates of the six commonest Australian and US strains of CA-MRSA were serially passaged daily for 25 days onto brain-heart infusion agar plates supplemented with 4 mu g/mL vancomycin and then subcultured for a further 15 days onto antibiotic-free agar to assess the stability of the resistance phenotype. Minimum inhibitory concentrations (MICs) were determined by standard Etest every 5 days from day 0 to day 40. Serial passaging resulted in increased MICs in all strains but the rises were modest, with an increase of < 2 doubling dilutions. All strains remained vancomycin Susceptible throughout the experiment according to Clinical Laboratory Standards Institute criteria. Crown Copyright (c) 2005 Published by Elsevier B.V. on behalf of International Society of Chemotherapy. All rights reserved.
Keyword Infectious Diseases
Microbiology
Pharmacology & Pharmacy
Staphylococcus Aureus
Glycopeptides
Vancomycin
Community-associated
Emergence
Q-Index Code C1
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2007 Higher Education Research Data Collection
School of Chemistry and Molecular Biosciences
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 6 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 20:01:32 EST